- Home
- EHTH vs DRUG Comparison
EHTH vs DRUG Comparison
Compare EHTH & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHTH
- DRUG
- Stock Information
- Founded
- EHTH 1997
- DRUG 2019
- Country
- EHTH United States
- DRUG United States
- Employees
- EHTH N/A
- DRUG N/A
- Industry
- EHTH Specialty Insurers
- DRUG Pharmaceuticals and Biotechnology
- Sector
- EHTH Finance
- DRUG Health Care
- Exchange
- EHTH Nasdaq
- DRUG Nasdaq
- Market Cap
- EHTH 292.7M
- DRUG 260.6M
- IPO Year
- EHTH 2006
- DRUG N/A
- Fundamental
- Price
- EHTH $10.05
- DRUG $35.99
- Analyst Decision
- EHTH Hold
- DRUG Strong Buy
- Analyst Count
- EHTH 5
- DRUG 4
- Target Price
- EHTH $7.70
- DRUG $84.33
- AVG Volume (30 Days)
- EHTH 288.4K
- DRUG 69.2K
- Earning Date
- EHTH 02-26-2025
- DRUG 03-04-2025
- Dividend Yield
- EHTH N/A
- DRUG N/A
- EPS Growth
- EHTH N/A
- DRUG N/A
- EPS
- EHTH N/A
- DRUG N/A
- Revenue
- EHTH $464,891,000.00
- DRUG N/A
- Revenue This Year
- EHTH $12.92
- DRUG N/A
- Revenue Next Year
- EHTH $5.43
- DRUG N/A
- P/E Ratio
- EHTH N/A
- DRUG N/A
- Revenue Growth
- EHTH 15.78
- DRUG N/A
- 52 Week Low
- EHTH $3.58
- DRUG $0.93
- 52 Week High
- EHTH $11.36
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- EHTH 51.88
- DRUG 43.58
- Support Level
- EHTH $9.20
- DRUG $40.10
- Resistance Level
- EHTH $11.07
- DRUG $47.50
- Average True Range (ATR)
- EHTH 0.63
- DRUG 3.56
- MACD
- EHTH -0.04
- DRUG -0.51
- Stochastic Oscillator
- EHTH 39.35
- DRUG 23.22
About EHTH eHealth Inc.
eHealth Inc is a company involved in private health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. The company operates its business in two segments: Medicare and Employer and Individual. It derives maximum revenue from Medicare Segment. All of the company's revenue is from the United States. It also has a presence in China.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.